CoronaVac COVID-19 Vaccine Less Effective in Scleroderma in Brazil

CoronaVac COVID-19 Vaccine Less Effective in Scleroderma in Brazil

315975

CoronaVac COVID-19 Vaccine Less Effective in Scleroderma in Brazil

People with systemic sclerosis (SSc) in Brazil had a weaker immune response to the CoronaVac COVID-19 vaccine than did healthy individuals, a study discovered. The findings also showed that treatment with the immunosuppressant therapy CellCept (mycophenolate mofetil) — an oral medication that improves lung function in SSc patients — impaired the vaccine-generated immune response. “This is the first study to specifically evaluate the deleterious effect of [CellCept] monotherapy in vaccine-induced antibody response in SSc patients,”…

You must be logged in to read/download the full post.